Available Trials

Advanced/Metastatic Malignancies

Bile Duct

  • STAR 16066

    A Phase 2, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Advanced/Metastatic or Surgically Unresectable Cholangiocarcionama Including FGFR2 Translocations Who Failed Previous Therapy

    Available at 8 locations

Breast Cancer

Head and Neck

Hematologic

Leukemia

Lung Cancer

  • STAR 15079

    A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study of the Efficacy and Safety of Lanreotide Autogel/ Depot 120mg plus BSC vs. Placebo plus BSC for Tumour Control in Subjects with Well Differentiated, Metastatic and/or Unresectable Typical or Atypical Lung Neuroendocrine Tumours

    Available at 8 locations

Lymphoma

  • STAR 16248

    An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects with Advanced Solid Tumors or with B Cell Lymphomas and Tazemetostat in Combination with Prednisolone in Subjects with Diffuse Large B Cell Lymphoma

    Available at 8 locations

  • STAR 11282

    A Phase 2 Open-Label Study of Brentuximab Vedotin in Front-Line Therapy of Hodkin Lymphoma (HL) in Adults Age 60 and Above

    Available at 8 locations

Multiple Myeloma

Myelofibrosis

  • STAR 17085

    An Open-Label Phase 2 Study of Itacitinib (INCB09110) in Combination with Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects with Myelofibrosis

    Available at 8 locations

Ovarian Cancer

Prostate Cancer

  • STAR 16238

    A Multicenter, Randomized, Open-Label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients with Metastatic Castration Resistant Prostate Cancer Associated with Homologous Recombination Deficiency

    Available at 8 locations

  • USOR 16237

    A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer Associated with Homologous Recombination Deficiency

    Available at 8 locations

Renal Cancer

Skin Cancer

  • STAR 17060

    A Phase II, Open-Labeled, Single Arm Study to Evaluate Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma

    Available at 8 locations

Solid Tumors

  • STAR 16248

    An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects with Advanced Solid Tumors or with B Cell Lymphomas and Tazemetostat in Combination with Prednisolone in Subjects with Diffuse Large B Cell Lymphoma

    Available at 8 locations

Rare Malignancies

Urothelial Cancer

  • STAR 15228

    A Phase 2, Open-Label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations

    Available at 8 locations